Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

#Cancer #Kanser #MemeKanseri #BreastCancer #Alpelisib #Elacestrant #MedSky #Sage

journals.sagepub.com/doi/10.1177/...

Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025 - OncoDaily Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025 / Breast Cancer, cancer, elacestrant,

Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- mBC at SABCS 2025

@sabcs.bsky.social

oncodaily.com/industry/ela...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Menarini #Elacestrant #ORSERDU #BreastCancer #SABCS2025

Menarini and Stemline Reveal Phase 2 Data for Elacestrant in Metastatic Breast Cancer Menarini and Stemline Therapeutics present pivotal Phase 2 results of Elacestrant (ORSERDU®) in ER+/HER2- metastatic breast cancer at the 2025 San Antonio Breast Cancer Symposium.

Menarini and Stemline Reveal Phase 2 Data for Elacestrant in Metastatic Breast Cancer #USA #New_York #Cancer_Research #Menarini #Elacestrant

Menarini Group Unveils Promising Phase 2 Elacestrant Data at San Antonio Breast Cancer Symposium Menarini Group and Stemline Therapeutics present promising findings on Elacestrant's effectiveness in treating ER+, HER2- metastatic breast cancer at SABCS 2025.

Menarini Group Unveils Promising Phase 2 Elacestrant Data at San Antonio Breast Cancer Symposium #USA #San_Antonio #Elacestrant #Menarini_Group #SABCS_2025

Menarini Group Unveils Promising Elacestrant Data for Breast Cancer Treatment The Menarini Group announces groundbreaking findings on Elacestrant for ER+, HER2- metastatic breast cancer at SABCS 2025, highlighting its effectiveness.

Menarini Group Unveils Promising Elacestrant Data for Breast Cancer Treatment #USA #Cancer_Research #San_Antonio #Menarini #Elacestrant

Menarini Group Unveils Significant Data for Elacestrant in ER+ HER2- Metastatic Breast Cancer at SABCS 2025 Discover groundbreaking results from Menarini Group's Elacestrant study for treating ER+, HER2- metastatic breast cancer, showcased at SABCS 2025.

Menarini Group Unveils Significant Data for Elacestrant in ER+ HER2- Metastatic Breast Cancer at SABCS 2025 #USA #New_York #Breast_Cancer #Elacestrant #Menarini_Group

Menarini Group Showcases Promising Elacestrant Data at 2025 SABCS for Breast Cancer Treatment Menarini Group, alongside Stemline Therapeutics, shares promising findings on Elacestrant's efficacy for treating ER+, HER2- metastatic breast cancer at the San Antonio Symposium.

Menarini Group Showcases Promising Elacestrant Data at 2025 SABCS for Breast Cancer Treatment #United_States #San_Antonio #Breast_Cancer #Elacestrant #Menarini_Group

Today at the #DGHO Annual Meeting 2025 #Cologne: #GBG presents exciting new research on combination therapy for #BRCA-mutated #breastcancer! Proud to share the #ELEMENT study #GBG114 — a randomized phase II trial exploring whether adding the oral #SERD #elacestrant to the #PARP inhibitor #olaparib.

Tumori: Binaschi (Menarini), 'elacestrant blocca crescita cancro seno metastatico' (Adnkronos) - "Elacestrant è una molecola orale che si lega al recettore dell'estrogeno, che nel carcinoma mammario metastatico è il carburante che fa crescere la cellula tumorale, e lo distrugge. Elacestrant è diventata il punto di ...

TI POTREBBE INTERESSARE: Tumori: Binaschi (Menarini), 'elacestrant blocca crescita cancro seno metastatico' ... LEGGI TUTTO #Tumori #Cancro #CarcinomaMammario #Elacestrant #Salute

Tumori, oncologa Del Mastro: "Elacestrant importante nel cancro mammario metastatico" (Adnkronos) - "Ogni anno in Italia sono circa 13mila i nuovi casi di carcinoma mammario metastatico e sono circa 40mila le donne che nel nostro Paese ci convivono. Nella maggior parte dei casi si tratta di donne con tumore della mammell...

TI POTREBBE INTERESSARE: Tumori, oncologa Del Mastro: "Elacestrant importante nel cancro mammario metastatico" ... LEGGI TUTTO #tumori #cancromammario #oncologia #elacestrant #salute

Tumori: Binaschi (Menarini), 'elacestrant blocca crescita cancro seno metastatico' (Adnkronos) - "Elacestrant è una molecola orale che si lega al recettore dell'estrogeno, che nel carcinoma mammario metastatico è il carburante che fa crescere la cellula tumorale, e lo distrugge. Elacestrant è diventata il punto di ...

È ACCADUTO IERI: Tumori: Binaschi (Menarini), 'elacestrant blocca crescita cancro seno metastatico' ... LEGGI TUTTO #tumori #cancro #elacestrant #cancerresearch #oncologia

Tumori: Binaschi (Menarini), 'elacestrant blocca crescita cancro seno metastatico' (Adnkronos) - "Elacestrant è una molecola orale che si lega al recettore dell'estrogeno, che nel carcinoma mammario metastatico è il carburante che fa crescere la cellula tumorale, e lo distrugge. Elacestrant è diventata il punto di ...

Tumori: Binaschi (Menarini), 'elacestrant blocca crescita cancro seno metastatico' ... LEGGI TUTTO #Tumore #Cancro #Seno #Metastatico #Elacestrant

Menarini Group Unveils Updated Findings on Elacestrant for Metastatic Breast Cancer at ASCO 2025 Menarini Group and Stemline Therapeutics present new data showcasing the efficacy of Elacestrant in treating ER+, HER2- metastatic breast cancer at ASCO 2025.

Menarini Group Unveils Updated Findings on Elacestrant for Metastatic Breast Cancer at ASCO 2025 #Italy #ORSERDU #Elacestrant #Florence #Menarini_Group

Menarini Group Highlights Elacestrant's Potential in Combination Therapy for ER+, HER2- Breast Cancer at ASCO 2025 Menarini Group shared promising updates on Elacestrant's effectiveness against ER+, HER2- metastatic breast cancer during ASCO 2025. The results emphasize its potential in combination therapies.

Menarini Group Highlights Elacestrant's Potential in Combination Therapy for ER+, HER2- Breast Cancer at ASCO 2025 #Italy #Menarini #Elacestrant #Florence #ASCO_2025

Menarini Group Unveils Promising Elacestrant Data at ASCO 2025 Annual Meeting Menarini Group showcases updated data on Elacestrant's effectiveness in treating ER+, HER2- metastatic breast cancer, highlighting its potential for combination therapy at ASCO 2025.

Menarini Group Unveils Promising Elacestrant Data at ASCO 2025 Annual Meeting #USA #Elacestrant #Florence #Menarini_Group #ASCO_2025

Menarini Group Showcases Latest Efficacy Data for Elacestrant in Breast Cancer at ASCO 2025 Menarini Group unveiled promising efficacy and safety data for Elacestrant combined with targeted therapies for ER+/HER2- metastatic breast cancer at ASCO 2025.

Menarini Group Showcases Latest Efficacy Data for Elacestrant in Breast Cancer at ASCO 2025 #Italy #Elacestrant #Florence #Menarini_Group #ASCO_2025

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety - Ünal Metin Tokat, Şevval Nur Bi... Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. ...

"Here we showed for the first time that an all-oral combination of elacestrant plus alpelisib was feasible, tolerable, and clinically active in an ESR1 and PIK3CA co-mutated and heavily pretreated patient."

#BreastCancer #MemeKanseri #Elacestrant #Alpelisib

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

#BreastCancer #PIK3CA #ESR1 #Elacestrant #MedSky #OncSky

Menarini and MEDSIR Unveil Phase III Study ADELA for Advanced Breast Cancer Treatment The ADELA study presented by Menarini and MEDSIR showcases a new therapy combining Elacestrant and Everolimus for advanced breast cancer, targeting treatment resistance.

Menarini and MEDSIR Unveil Phase III Study ADELA for Advanced Breast Cancer Treatment #Italy #Breast_Cancer #Elacestrant #Florence #Everolimus

Menarini Group Showcases Enhanced ORSERDU® Data at 2024 San Antonio Breast Cancer Symposium At the upcoming SABCS 2024, Menarini will unveil new data underlining ORSERDU®'s effectiveness in advanced breast cancer treatment, highlighting its clinical significance.

Menarini Group Showcases Enhanced ORSERDU® Data at 2024 San Antonio Breast Cancer Symposium #USA #San_Antonio #ORSERDU #Elacestrant #Menarini_Group

Menarini Group Unveils Key Data on ORSERDU® for Metastatic Breast Cancer at 2024 Symposium Menarini Group showcases groundbreaking data on ORSERDU® at the 2024 San Antonio Breast Cancer Symposium, emphasizing its critical role for mBC patients.

Menarini Group Unveils Key Data on ORSERDU® for Metastatic Breast Cancer at 2024 Symposium #USA #San_Antonio #Menarini #Elacestrant #ORSERDU®

Menarini Group Showcases New Insights on ORSERDU at 2024 San Antonio Breast Cancer Symposium Menarini Group presents groundbreaking data on ORSERDU for ER+, HER2- advanced breast cancer at the 2024 SABCS, highlighting its real-world efficacy.

Menarini Group Showcases New Insights on ORSERDU at 2024 San Antonio Breast Cancer Symposium #Italy #ORSERDU #Menarini #Elacestrant #Florence